http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014148432-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9a5e842d166570d1662863c1235785a2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_79a8b02274665fc26918290dfdfa644e |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D211-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4725 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-22 |
| filingDate | 2014-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_498b28578e775db5a3795e3ca7d1f03e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b691d412b539d1bb411a17250f18e8d0 |
| publicationDate | 2014-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2014148432-A1 |
| titleOfInvention | Compounds for the Treatment of Neurological Disorders |
| abstract | Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of certain neurologic disorders, including disorders related to NMDA receptor activation, including neuropsychiatric disorders, neurodegenerative diorders and other neurologic diseases, disorders and conditions including stroke, brain injury, epilepsy, neuropsychiatric disorders, mood disorders, chronic pain and related conditions. The compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof are provided: n n n n n n n n n n wherein Ar 1 and Ar 2 are independently substituted or unsubstituted aryl, heteroaryl or heterocycle;n nm, n, p and q are each independently 0, 1 or 2;n nA is a bond, CH 2 , CH═CH, C≡C, NR, O or S;n nEach R 3 is independently selected from C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 haloalkyl, OH, O-alkyl, O-aryl, SH, S-alkyl, fluoro, chloro, bromo, iodo, nitro, or cyano;n nQ is selected from CH 2 , CHR, CR 2 , NH, NR, O and S;n nEach Y is independently CR 2 or CR 2 CR 2 ;n neach R is independently selected from H, OH or alkyl, in particular C 1-4 alkyl;n nX is O, S, or CH 2 ; andn nZ is OH, NR 6 R 7 , NR 8 SO 2 (C 1 -C 6 alkyl), NR 8 C(O)NR 6 R 7 , NR 8 C(S)NR 6 R 7 , NR 8 CHO, NR 8 C(O)(C 1 -C 6 alkyl), NR 8 C(O)O(C 1 -C 6 alkyl), NR 8 -dihydrothiazole, or NR 8 -dihydroimidazole wherein each R 6 , R 7 and R 8 is independently H, C 1 -C 6 alkyl or C 6 -C 12 aralkyl; or Z comes together with Ar 2 together to form a substituted or unsubstituted heterocyclic ring system with Ar 2 . |
| priorityDate | 2009-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1171.